• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Scores of Child-Pugh Classification Impact Overall Survival After Stereotactic Body Radiation Therapy for Primary and Metastatic Liver Tumors.儿童-普奇分类评分影响原发性和转移性肝肿瘤立体定向体部放射治疗后的总生存期。
J Clin Exp Hepatol. 2020 Mar-Apr;10(2):101-105. doi: 10.1016/j.jceh.2019.05.002. Epub 2019 May 21.
2
Hepatocellular carcinoma with child Pugh-A Cirrhosis treated with stereotactic body radiotherapy.采用立体定向体部放疗治疗的伴有Child Pugh-A级肝硬化的肝细胞癌
World J Gastrointest Surg. 2017 Dec 27;9(12):256-263. doi: 10.4240/wjgs.v9.i12.256.
3
Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.立体定向体部放疗治疗小肝癌的疗效及相关预测因素:一项观察性研究的系统评价和荟萃分析。
Radiat Oncol. 2021 Apr 8;16(1):68. doi: 10.1186/s13014-021-01761-1.
4
The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).不可切除肝细胞癌(HCC)的挑战:一项关于立体定向体部放射治疗(SBRT)的单机构经验结果
J Cancer Res Clin Oncol. 2015 Jul;141(7):1301-9. doi: 10.1007/s00432-015-1929-y. Epub 2015 Feb 3.
5
Stereotactic Body Radiotherapy for Inoperable Liver Tumors: Results of a Single Institutional Experience.立体定向体部放射治疗不可切除性肝肿瘤:单机构经验结果
Cureus. 2016 Dec 20;8(12):e935. doi: 10.7759/cureus.935.
6
Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment.加速分割低剂量立体定向放疗治疗不同程度肝损害的肝细胞癌患者的安全性和疗效。
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):577-585. doi: 10.1016/j.ijrobp.2017.11.030. Epub 2017 Nov 27.
7
Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.对于直径大于5厘米的不可切除肝细胞癌,经动脉栓塞联合立体定向体部放疗与立体定向体部放疗单药治疗的长期生存分析
BMC Cancer. 2016 Nov 3;16(1):834. doi: 10.1186/s12885-016-2894-9.
8
Efficacy and Dose-Response Relationship of Stereotactic Body Radiotherapy for Abdominal Lymph Node Metastases from Hepatocellular Carcinoma.立体定向体部放疗治疗肝细胞癌腹腔淋巴结转移的疗效及剂量反应关系。
Oncologist. 2023 Jun 2;28(6):e369-e378. doi: 10.1093/oncolo/oyad083.
9
High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma.高剂量立体定向体放射治疗可提高不能手术的肝细胞癌患者的局部控制率和总生存率。
Radiat Oncol. 2013 Oct 27;8:250. doi: 10.1186/1748-717X-8-250.
10
Effects of stereotactic body radiotherapy for clinical outcomes of patients with liver metastasis and hepatocellular carcinoma: A retrospective study.立体定向体部放疗对肝转移和肝细胞癌患者临床结局的影响:一项回顾性研究。
Oncol Lett. 2023 May 31;26(1):305. doi: 10.3892/ol.2023.13891. eCollection 2023 Jul.

引用本文的文献

1
ACROPath Oligometastases: The American College of Radiation Oncology Clinical Pathway.ACRO 寡转移瘤:美国放射肿瘤学会临床路径
Cureus. 2024 Nov 20;16(11):e74098. doi: 10.7759/cureus.74098. eCollection 2024 Nov.
2
APESTNet with Mask R-CNN for Liver Tumor Segmentation and Classification.用于肝脏肿瘤分割与分类的带掩码区域卷积神经网络的APEST网络
Cancers (Basel). 2023 Jan 4;15(2):330. doi: 10.3390/cancers15020330.
3
Efficacy and Safety of the Radiotherapy for Liver Cancer: Assessment of Local Controllability and its Role in Multidisciplinary Therapy.肝癌放疗的疗效与安全性:局部可控性评估及其在多学科治疗中的作用
Cancers (Basel). 2020 Oct 13;12(10):2955. doi: 10.3390/cancers12102955.

本文引用的文献

1
Stereotactic Body Radiotherapy for Small Unresectable Hepatocellular Carcinomas.立体定向体部放疗治疗不可切除的小肝癌。
Clin Oncol (R Coll Radiol). 2019 Jun;31(6):365-373. doi: 10.1016/j.clon.2019.01.012. Epub 2019 Feb 18.
2
Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy.立体定向体部放疗治疗乳腺癌肝转移的疗效观察。
Breast. 2018 Dec;42:150-156. doi: 10.1016/j.breast.2018.09.006. Epub 2018 Sep 29.
3
Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis.SBRT 与 TACE 治疗 HCC 患者的局部肿瘤控制比较:倾向评分分析。
BMC Cancer. 2018 Aug 9;18(1):807. doi: 10.1186/s12885-018-4696-8.
4
Stereotactic body radiation therapy for centrally located hepatocellular carcinoma: outcomes and toxicities.立体定向体部放射治疗中央型肝癌:疗效和毒性。
J Cancer Res Clin Oncol. 2018 Oct;144(10):2077-2083. doi: 10.1007/s00432-018-2729-y. Epub 2018 Aug 7.
5
Is higher dose always the right answer in stereotactic body radiation therapy for small hepatocellular carcinoma?在小肝细胞癌的立体定向体部放射治疗中,高剂量总是正确答案吗?
Radiat Oncol J. 2018 Jun;36(2):129-138. doi: 10.3857/roj.2017.00598. Epub 2018 Jun 29.
6
Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease.立体定向体部放射治疗(SBRT)治疗肝细胞癌合并寡转移肝脏疾病患者。
Radiat Oncol. 2018 May 29;13(1):100. doi: 10.1186/s13014-018-1048-4.
7
Stereotactic Body Radiation Therapy in Primary and Metastatic Liver Disease.立体定向体部放射治疗在原发性和转移性肝脏疾病中的应用
Anticancer Res. 2017 Dec;37(12):7005-7010. doi: 10.21873/anticanres.12169.
8
Local Control Outcomes Using Stereotactic Body Radiation Therapy for Liver Metastases From Colorectal Cancer.立体定向体部放射治疗用于结直肠癌肝转移的局部控制结果
Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):876-883. doi: 10.1016/j.ijrobp.2017.07.030. Epub 2017 Jul 31.
9
Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.肝细胞癌立体定向体部放射治疗的进展
Semin Radiat Oncol. 2017 Jul;27(3):247-255. doi: 10.1016/j.semradonc.2017.02.002. Epub 2017 Feb 20.
10
Stereotactic Body Radiotherapy for Liver Metastases.肝脏转移瘤的立体定向体部放射治疗
Semin Radiat Oncol. 2017 Jul;27(3):240-246. doi: 10.1016/j.semradonc.2017.02.004. Epub 2017 Feb 20.

儿童-普奇分类评分影响原发性和转移性肝肿瘤立体定向体部放射治疗后的总生存期。

Scores of Child-Pugh Classification Impact Overall Survival After Stereotactic Body Radiation Therapy for Primary and Metastatic Liver Tumors.

作者信息

Tanaka Osamu, Kojima Takao, Ohbora Akihiro, Makita Chiyoko, Taniguchi Takuya, Ono Kousei, Matsuo Masayuki, Nagata Yasushi

机构信息

Asahi University Hospital, Department of Radiation Oncology, Gifu, Japan.

Asahi University Hospital, Department of Gastroenterology, Gifu, Japan.

出版信息

J Clin Exp Hepatol. 2020 Mar-Apr;10(2):101-105. doi: 10.1016/j.jceh.2019.05.002. Epub 2019 May 21.

DOI:10.1016/j.jceh.2019.05.002
PMID:32189924
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7068027/
Abstract

BACKGROUND

Stereotactic body radiotherapy (SBRT) delivers high-dose radiation to tumor tissues in few fractions, thereby reducing radiation damage to at-risk organs. There are more potential effects of SBRT owing to the higher biological equivalent dose delivered. Herein, we retrospectively analyzed its effectiveness and toxicity at our institution.

METHODS

Data from patients with hepatocellular carcinoma (HCC; n = 10) and liver metastases (n = 10) who underwent SBRT (total dose of 30-50 Gy in 5-10 fractions) between 2013 and 2016 were analyzed. Adverse events were recorded at the end of RT, 6 months after treatment, or upon death. Overall survival (OS) was calculated according to the biological effective dose (BED α/β = 10) and liver function (Child-Pugh [CP] classification 5 or 6 vs. 7 or 8) after SBRT, using Kaplan-Meier analyses.

RESULTS

Of the 20 patients, 6 declined the CP classification score after SBRT; grade 3 adverse events were not seen in any patient. A higher OS rate was seen in patients receiving a higher BED and in those with better CP classification after SBRT. Kaplan-Meier survival analysis yielded a median OS of 401 days and 1- and 2-year OS of 45% and 15%, respectively.

CONCLUSION

The higher BED was significantly associated with tumor control, and there were no differences in the tumor control rate between HCC and metastatic tumors. Changes in CP scores after SBRT also affected the survival rate. Good liver function may permit multiple rounds of SBRT.

摘要

背景

立体定向体部放疗(SBRT)可在少数分次治疗中向肿瘤组织输送高剂量辐射,从而减少对危及器官的辐射损伤。由于所输送的生物等效剂量较高,SBRT存在更多潜在效应。在此,我们回顾性分析了其在本机构的有效性和毒性。

方法

分析了2013年至2016年间接受SBRT(总剂量30 - 50 Gy,分5 - 10次)的肝细胞癌(HCC;n = 10)和肝转移瘤(n = 10)患者的数据。在放疗结束时、治疗后6个月或死亡时记录不良事件。使用Kaplan - Meier分析方法,根据SBRT后的生物有效剂量(BED α/β = 10)和肝功能(Child - Pugh [CP]分级5或6与7或8)计算总生存期(OS)。

结果

20例患者中,6例在SBRT后拒绝进行CP分级评分;未观察到任何患者出现3级不良事件。接受较高BED的患者以及SBRT后CP分级较好的患者的OS率较高。Kaplan - Meier生存分析得出中位OS为401天,1年和2年OS分别为45%和15%。

结论

较高的BED与肿瘤控制显著相关,HCC和转移性肿瘤之间的肿瘤控制率无差异。SBRT后CP评分的变化也影响生存率。良好的肝功能可能允许进行多轮SBRT。